ClinicalTrials.gg
CompletedNCT00002399Updated Jun 24, 2005

A Comparison of SCH 56592 and Fluconazole in the Treatment of Oropharyngeal Candidiasis (OPC) in HIV-Positive Patients

A Phase 2 interventional study of Posaconazole and Fluconazole in Candidiasis, Oral and HIV Infections, sponsored by Schering-Plough. Completed at 53 sites in 18 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2005-06-24.

Sponsored by Schering-Plough (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
500
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies in Candidiasis, Oral with a site in United States — 2 open to participants now, 2 under way, none of them phase 3. Candidiasis, Oral · United States.

Enrollment
2nd of 13
500 · median 70
Phase 2
4 of 26
none open now
Registered
1st of 26
by date
Lead sponsor
2 of 26
Schering-Plough

Among the 26 studies in Candidiasis, Oral with a site in United States, this one is the 2nd largest by enrollment of the 13 interventional ones that give a count, is one of 4 in phase 2, and was the 1st registered.

Candidiasis, Oral

48 studies on the registry are indexed under Candidiasis, Oral; 6 are open to participants now.

Browse Candidiasis, Oral studies →

Open to participants now

2 of the 26 studies in Candidiasis, Oral with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 3 Candidiasis, Oral studies recruiting now, 2 set no upper age limit and 1 stops at 75 or younger; 2 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Candidiasis, Oral with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to compare the safety and effectiveness of SCH 56592 with that of fluconazole in the treatment of OPC (a fungal infection of the throat) in HIV-positive patients.

Read the detailed description

This is a randomized, multicenter, double-blind study consisting of 5 arms (4 dose levels of SCH 56592 vs fluconazole) in the treatment of oropharyngeal candidiasis (OPC) in HIV-positive patients.

03

Conditions studied

  • Candidiasis, Oral
  • HIV Infections

Keywords

  • AIDS-Related Opportunistic Infections
  • Fluconazole
  • Antifungal Agents
  • Candidiasis
  • Triazoles
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients must have:

  • Documented seropositivity (by Western blot or other approved confirmatory test) prior to enrollment.
  • Pseudomembranous oropharyngeal candidiasis.
  • Fungal stain or KOH consistent with Candida species, confirmed by a positive mycologic culture.
  • Ability to swallow study medication.

Exclusion criteria

Exclusion Criteria

Co-existing Condition:

Patients with any of the following symptoms and conditions are excluded:

  • Medical condition requiring use of prohibited drugs.
  • Primary seroconversion-related mucosal candidiasis.
  • Systemic candidiasis.
  • All forms of OPC other than pseudomembranous (unless accompanied by pseudomembranous OPC).
  • Documented or suspected fungal esophagitis in patients with symptoms of esophagitis.
  • with prolonged or clinically-significant abnormalities.

Concurrent Medication:

Excluded:

  • Systemic antifungals (IV or oral).
  • Topical oral antifungals, e.g., Nystatin, Mycelex, etc.
  • Medications known to interact with azoles and that may lead to life-threatening side effects:
  • terfenadine, astemizole, cisapride, ebastine, triazolam, midazolam.
  • Medications known to lower the serum concentration/efficacy of azole antifungals:
  • rifampin, carbamazepine, phenytoin, rifabutin, barbiturates, isoniazid, H2 blockers.
  • Cytokines (except erythropoietin), interferon, or lymphocyte replacement therapy unless patient already taking these agents for at least 30 days prior to enrollment.
  • Protease inhibitors, starting for the first time, 30 days prior to study enrollment.
  • Cytotoxic therapy for cancer.
  • Oral or intravenous at supraphysiologic doses (prednisone 10 mg/day or greater; hydrocortisone 40 mg/day or greater; dexamethasone 2 mg/day or greater.

Patients with any of the following prior conditions are excluded:

  • Prior enrollment in this study.
  • Less than 3 months .
  • History of to azole antifungals.
  • History of failed therapy with fluconazole 100 mg/day for 2 weeks in the last 3 months.

Prior Medication:

Excluded (wash-outs for medications):

  • Systemic antifungals (IV, oral) within 14 days prior to enrollment.
  • Topical oral antifungals within 1 day prior to enrollment.
  • Oral or intravenous corticosteroids at supraphysiologic doses within 10 days prior to enrollment.
  • Astemizole within 10 days prior to enrollment.
  • Drugs known to lower the serum concentration/efficacy of azole antifungals within 30 days prior to enrollment.
  • drug (unlicensed new chemical entity) use within 30 days prior to enrollment.

Current known drug abuse, in the opinion of the lead investigator, that would interfere with the subject's participation in the study.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Masking
Double
Enrollment
500 participants

Interventions

06

Study locations

53 sites
  • Tucson Veterans Administration Med Ctr
    Tucson, Arizona 85723, United States
  • Northeast Arkansas Clinic
    Jonesboro, Arkansas 72401, United States
  • Miami Veterans Administration Med Ctr
    Miami, Florida 33125, United States
  • Mercy Hosp
    Miami, Florida 33133, United States
  • Ponce de Leon Med Ctr
    Atlanta, Georgia 30308, United States
  • Med College of Georgia
    Augusta, Georgia 30912, United States
  • Rush Med College / Rush Presbyterian - St Luke's Med Cen
    Chicago, Illinois 60612, United States
  • Wishard Hosp
    Indianapolis, Indiana 46202, United States
  • Wayne State Univ / Harper Hosp
    Detroit, Michigan 48201, United States
  • St Michaels Med Ctr
    Newark, New Jersey 07102, United States
  • Duke Univ Med Ctr
    Durham, North Carolina 27710, United States
  • Thomas Jefferson Univ / Division of Infectious Disease
    Philadelphia, Pennsylvania 19107, United States
  • Vanderbilt Univ Med Ctr
    Nashville, Tennessee 372321302, United States
  • Univ of Texas Southwestern Med Ctr
    Dallas, Texas 75390, United States
  • Univ of Texas / Med School at Houston
    Houston, Texas 77030, United States
  • Univ of Texas Health Sciences Ctr
    San Antonio, Texas 78284, United States
  • Infections Ltd / Physicians Med Ctr
    Tacoma, Washington 98405, United States
  • Centro de Micologia / Facultad de Medicina UBA
    Buenos Aires, Argentina
  • Hosp Fernandez
    Buenos Aires, Argentina
  • CHU Saint Pierre
    Brussels, Belgium
  • St Paul's Hosp
    Vancouver, British Columbia, Canada
  • Victoria Gen Hosp
    Halifax, Nova Scotia, Canada
  • Montreal Gen Hosp
    Montreal, Quebec, Canada
  • Fundacion Arriaran
    Santiago, Chile
  • Avenida Lope de Vega Avenue esq/Calle Jose Amado Soler
    Ensanche NACO/ Santo Domingo, Dominican Republic
  • Faculty of Medicine / Dept of Internal Medicine
    Addis Ababa, Ethiopia
  • Hopital Raymond Poincare
    Garches, France
  • Hopital de La Conception
    Maseille, France
  • Hopital Guy de Chauliac Service des Maladies Infectieuses
    Montpellier, France
  • Service des Maladies Infectieuses Hopital de l Archet
    Nice, France
  • Hopital de l Institut Pasteur
    Paris cedex, France
  • Hopital Rothchild
    Paris, France
  • Service des Maladies Infectieuses
    Tours Cedex, France
  • Service des Maladies Infectieuses
    Villejuif Cedex, France
  • Rheinische Friedrich Wilhelms Universitaet Medizinische
    Bonn, Germany
  • Heinrich Heine Universitat
    Dusseldorf, Germany
  • Allgemeines Krankenhaus St Georg
    Hamburg, Germany
  • Universitaets Krankenhaus Eppendorf Medizinische Kernklinik
    Hamburg, Germany
  • Staedtisches Krankenhaus Kiel
    Kiel, Germany
  • Universitaet Klinik Koln
    Koln, Germany
  • Universitat Munchen / Medizinische Poliklinik
    Munich 2, Germany
  • Hosp Roosevelt Chief Infectious Diseases Unit
    Guatemala, Guatemala
  • Hosp Regional del Seguro Social
    San Pedro Sula, Honduras
  • Sheba Med Ctr
    Tel Hashomer, Israel
  • Hosp de Especialidades Centro Medico La Raza
    Mexico, Mexico
  • Royal Ctr
    Panama, Panama
  • Daniel Rudolph Malan
    Port Elizabeth, South Africa
  • The Studio
    Rosebank, South Africa
  • Univ of Stellenbosch Med School Depart Med Phys
    Tygerberg, South Africa
  • Hosp Clinic
    Barcelona, Spain
  • Hosp Valle D Hebron
    Barcelona, Spain
  • Program on AIDS / Thai Red Cross Society
    Bangkok, Thailand
  • Policlinica Metropolitana
    Caracas, Venezuela
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 24, 2005, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00002399
Lead sponsor
Schering-Plough
First posted
Aug 31, 2001
Last update
Jun 24, 2005
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 1999. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluconazole

Start the discussion